The U.S. Supreme Court ruled Thursday that Hikma Pharmaceuticals did not infringe patents by selling a generic version of the cardiovascular drug Vascepa [1].
The decision preserves the "skinny label" pathway, a legal mechanism that allows generic drugmakers to omit patented uses from their labeling to enter the market sooner. This ruling prevents brand-name pharmaceutical companies from blocking generic competitors who avoid promoting a drug for specific, patented indications.
The court's decision was unanimous [4]. It affirmed a lower court's dismissal of an infringement suit brought by Amarin Pharma, the manufacturer of Vascepa [1], [2]. The justices said that Hikma's marketing did not encourage the patented use of the medication [2].
The legal battle reached the high court after a hearing on April 29, 2026 [3]. The central issue was whether a generic manufacturer can be held liable for patent infringement if the drug is used for a patented purpose, even if the label does not explicitly instruct the user to do so.
By upholding the district-court judge's ruling, the Supreme Court ensures that generic companies can continue to carve out specific uses from their labels, a practice known as skinny labeling, without facing immediate patent litigation [1], [2]. Hikma Pharmaceuticals, which trades under the ticker HKMPF [4], successfully defended its right to market the generic alternative without infringing on Amarin's intellectual property [1].
The outcome provides a significant victory for the generic drug industry by maintaining a predictable legal framework for competition. It limits the ability of brand-name firms to extend their market exclusivity through aggressive patent enforcement against labels that omit specific claims [2].
“The court's decision was unanimous.”
This ruling reinforces the legal viability of 'skinny labels,' ensuring that generic drug manufacturers can enter the market by simply omitting patented indications from their product inserts. By preventing brand-name companies from claiming 'induced infringement' in these cases, the court has lowered the risk for generics and potentially accelerated the availability of lower-cost medications for patients.
